Show simple item record

dc.contributor.authorBahlis, NJ
dc.contributor.authorCorso, A
dc.contributor.authorMugge, LO
dc.contributor.authorShen, ZX
dc.contributor.authorDesjardins, P
dc.contributor.authorStoppa, AM
dc.contributor.authorDecaux, O
dc.contributor.authorDe Revel, T
dc.contributor.authorGranell, M
dc.contributor.authorMarit, G
dc.contributor.authorNahi, H
dc.contributor.authorDemuynck, H
dc.contributor.authorHuang, SY
dc.contributor.authorBasu, Supratik
dc.contributor.authorGuthrie, TH
dc.contributor.authorErvin-Hayes, A
dc.contributor.authorMarek, J
dc.contributor.authorChen, G
dc.contributor.authorFacon, T
dc.date.accessioned2020-08-28T10:29:35Z
dc.date.available2020-08-28T10:29:35Z
dc.date.issued2017-11-01
dc.identifier.citationBahlis, N. J., Corso, A., Mugge, L.-O., Shen, Z.-X. et al (2017) Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial, Leukemia, 31, pp. 2435–2442. DOI: 10.1038/leu.2017.111en
dc.identifier.issn0887-6924en
dc.identifier.pmid28373701 (pubmed)
dc.identifier.doi10.1038/leu.2017.111en
dc.identifier.urihttp://hdl.handle.net/2436/623539
dc.description© 2017 The Authors. Published by Nature Publishing Group. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1038/leu.2017.111en
dc.description.abstract© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thalidomide for 12 cycles (MPT) and Rd for 18 cycles (Rd18) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) showed that Rd continuous prolonged progression-free survival and overall survival compared with MPT. A subanalysis of the FIRST trial was conducted to determine the benefits of Rd continuous in patients with NDMM based on depth of response. Patients randomized 1:1:1 to Rd continuous, Rd18 or MPT were divided into subgroups based on best response: complete response (CR; n=290), ≥ very good partial response (VGPR; n=679), ≥ partial response (PR; n=1 225) or ≤ stable disease (n=299). Over 13% of patients receiving Rd continuous who achieved ≥ VGPR as best response did so beyond 18 months of treatment. Rd continuous reduced the risk of progression or death by 67%, 51% and 35% vs MPT in patients with CR, ≥ VGPR and ≥ PR, respectively. Similarly, Rd continuous reduced the risk of progression or death by 61%, 54% and 38% vs Rd18 in patients with CR, ≥ VGPR and ≥ PR, respectively. In patients with CR, ≥ VGPR or ≥ PR, 4-year survival rates in the Rd continuous arm (81.1%, 73.1% or 64.6%, respectively) were higher vs MPT (70.8%, 59.8% or 57.2%, respectively) and similar vs Rd18 (76.5%, 67.7% and 62.5%, respectively). Rd continuous improved efficacy outcomes in all responding patients, including those with CR, compared with fixed duration treatment.en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherSpringer Science and Business Media LLCen
dc.relation.urlhttps://www.nature.com/articles/leu2017111en
dc.rightsLicence for published version: Creative Commons Attribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectchemotherapyen
dc.subjectmyelomaen
dc.subject.meshHumans
dc.subject.meshMultiple Myeloma
dc.subject.meshThalidomide
dc.subject.meshMelphalan
dc.subject.meshPrednisone
dc.subject.meshDexamethasone
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshMiddle Aged
dc.subject.meshFemale
dc.subject.meshMale
dc.titleBenefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trialen
dc.typeJournal articleen
dc.identifier.eissn1476-5551
dc.identifier.journalLeukemiaen
dc.date.updated2020-08-24T09:24:44Z
dc.contributor.institutionTom Baker Cancer Center-University of Calgary, Calgary, Alberta, Canada.
pubs.place-of-publicationEngland
dc.date.accepted2017-03-21
rioxxterms.funderCelgene Corporationen
rioxxterms.identifier.projectUOW28082020SBen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2020-08-28en
dc.source.volume31
dc.source.issue11
dc.source.beginpage2435
dc.source.endpage2442
dc.description.versionPublished version
refterms.dateFCD2020-08-28T10:27:33Z
refterms.versionFCDVoR
refterms.dateFOA2020-08-28T00:00:00Z


Files in this item

Thumbnail
Name:
Basu_Benefit_Of_Continuous_2020.pdf
Size:
2.002Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Licence for published version: Creative Commons Attribution 4.0 International
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International